## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.5% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($121.54)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment**
- Source: Finviz | 20251230T174600 | Bullish | Relevance: 100%
- Abbott Laboratories (ABT) has received FDA approval for its Volt™ PFA System, designed to treat patients with atrial fibrillation (AFib). This system will soon be commercially available in the U.S. and is already expanding in the EU after CE Mark approval. The approval follows the VOLT-AF IDE study, which demonstrated the system's safety and effectiveness for both paroxysmal and persistent AFib.

**2. Traders Buy Large Volume of Call Options on Abbott Laboratories (NYSE:ABT)**
- Source: MarketBeat | 20251230T212543 | Bullish | Relevance: 100%
- Traders have significantly increased their bullish sentiment on Abbott Laboratories (NYSE:ABT), buying an unusually high volume of call options. This activity follows Abbott raising its quarterly dividend and reaffirming its strong financial guidance for FY2025, contributing to a positive stock performance. The company maintains a "Moderate Buy" consensus rating with an average price target of $147.

**3. Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment**
- Source: Insider Monkey | 20251230T174600 | Bullish | Relevance: 100%
- Abbott Laboratories (NYSE: ABT) has received FDA approval for its Volt™ PFA System, designed to treat patients with atrial fibrillation (AFib). This device offers a new treatment option for the approximately 12 million people in the U.S. over 65 who suffer from AFib, a condition that significantly increases the risk of stroke. The approval follows successful clinical trials and previous CE Mark approval in the European Union, with commercial use expected to begin soon in the U.S.

**4. Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger**
- Source: The Globe and Mail | 20251230T141229 | Somewhat-Bullish | Relevance: 100%
- Exact Sciences (EXAS) has approved the acceleration of executive bonuses and the vesting of certain restricted stock units and performance share units for fiscal year 2025. This decision, made on December 23, 2025, addresses potential tax implications related to its impending acquisition by Abbott Laboratories, which was announced on November 19, 2025. The arrangements include clawback provisions and potential true-up payments to align executive compensation with the merger structure while managing excise tax exposure.

**5. Oak Harvest Investment Services Decreases Stake in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251230T122054 | Somewhat-Bullish | Relevance: 100%
- Oak Harvest Investment Services significantly reduced its stake in Abbott Laboratories by 41.5% in Q3 2025, selling 36,011 shares and retaining 50,712 shares valued at $6.79 million. Despite this, Abbott Laboratories reported strong Q3 EPS in line with expectations and raised its quarterly dividend, while institutional ownership remains high at 75.18%. Analysts have an average target price near $147 for the stock, rating it a "Moderate Buy."

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +2.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.2x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.9B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.2 |
| Current P/E | 24.3 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.9% to 0.5% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 50. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.54% (CS: 58) | Neutral |
| RSI_14 | 50.4 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 0.967x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.82
- **Stop Loss:** $121.54 (3.4% risk)
- **Target:** $130.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 308
- **Position Value:** $38,752.56
- **Portfolio %:** 38.75%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*